Advertisement
| reaps pharma llc: Make Talent Your Business Wendy Axelrod, Jeannie Coyle, 2011-06-06 Despite considerable investment in resources and tools, many companies struggle to meet the demand for the talent they require. Make Talent Your Business” gets to the heart of the matter: Managers themselves are in the best position to help people learn from experience (the uncontested major source of development) and shows managers how to do it by using the five practices that work for managers who are exceptional at building talent. This set of practices goes well beyond the usual managerial coaching and performance management. It moves the focus from performance today to development of skills that truly raise the game of employees—skills such as in-the-moment judgment, customer relationship building and collaborative decision-making. Managers who grow talent enhance their own reputations and get better results, retain people, attract talent and make their organizations more agile and capable to deal with future challenges. |
| reaps pharma llc: Comprehensive Pharmacy Review for NAPLEX Leon Shargel, Alan H. Mutnick, Paul F. Souney, Larry N. Swanson, 2012-10-01 This eighth edition of Comprehensive Pharmacy Review reflects the continuing evolution of pharmacy practice and educational requirements. The main objective of the book is to provide a comprehensive study guide for pharmacy students and other candidateswho are preparing for the North American Pharmacist Licensure Examination (NAPLEX). This volume represents the contributions of more than 50 specialists who provide wide expertise in pharmaceutical science, pharmacy practice, and clinical pharmacy. Theircontributions to Comprehensive Pharmacy Review assure that this review guide is accurate and current as well as written in a comprehensible manner for students, teachers, and practitioners alike. This review publication, along with the separate booklet of simulated NAPLEX exams (Comprehensive Pharmacy Review Practice Exams, 8th edition), provides both guidance and test practice for NAPLEX candidates--Provided by publisher. |
| reaps pharma llc: Digital Strategies in the Pharmaceutical Industry L. Lerer, M. Piper, 2003-01-24 This book is a comprehensive review of the current state of digital innovation, Internet activity and e-business in the life sciences arena and a practical guide for managers planning, developing and implementing e-strategies in the pharmaceutical industry. The authors provide numerous examples of innovative, best practice and lay the strategic foundation for using e-business across the pharmaceutical value chain from drug discovery to physician promotion to direct-to-consumer marketing. |
| reaps pharma llc: Generic Drug Product Development Isadore Kanfer, Leon Shargel, 2016-04-19 Due to a worldwide need for lower cost drug therapy, use of generic and multi-source drug products have been increasing. To meet international patent and trade agreements, the development and sale of these products must conform to national and international laws, and generic products must prove that they are of the same quality and are therapeutica |
| reaps pharma llc: Avoiding Opioid Abuse While Managing Pain Lynn R. Webster, Beth Dove, 2007 Prescription opioids are dangerous in the hands of drug abusers, but they are also beneficial or even lifesaving for millions of people who otherwise would live with chronic pain. Clinicians who prescribe opioids are often caught between their professional obligation to relieve suffering and their desire to avoid contributing to the nonmedical consumption of controlled substances. |
| reaps pharma llc: World Investment Report 2019 United Nations Publications, 2019-08-16 This report focuses on special economic zones (SEZs) which are widely used across most developing and many developed economies. It explores the place of SEZs in today's global investment landscape and provides guidance for policymakers on how to make SEZs work for sustainable development. It presents international investment trends and prospects at global, regional and national levels, as well as the evolution of international production and global value chains. It analyses the latest developments in new policy measures for investment promotion, facilitation and regulation around the world. |
| reaps pharma llc: Transition and Coherence in Intellectual Property Law Niklas Bruun, Graeme B. Dinwoodie, Marianne Levin, Ansgar Ohly, 2021-01-07 This volume is for students and scholars of intellectual property law, practitioners seeking creative arguments from across the field, and policymakers searching for solutions to changing social and technological issues. The book explores the tensions between two fundamentally competing demands made of IP law. |
| reaps pharma llc: Pharmaceutical Pricing Compendium Urch Publishing, 2003-03-01 |
| reaps pharma llc: Generic Drug Product Development Leon Shargel, Isadore Kanfer, 2013-10-24 In this era of increased pharmaceutical industry competition, success for generic drug companies is dependent on their ability to manufacture therapeutic-equivalent drug products in an economical and timely manner, while also being cognizant of patent infringement and other legal and regulatory concerns.Generic Drug Product Development: Solid Oral |
| reaps pharma llc: Earnings Management Joshua Ronen, Varda Yaari, 2008-08-06 This book is a study of earnings management, aimed at scholars and professionals in accounting, finance, economics, and law. The authors address research questions including: Why are earnings so important that firms feel compelled to manipulate them? What set of circumstances will induce earnings management? How will the interaction among management, boards of directors, investors, employees, suppliers, customers and regulators affect earnings management? How to design empirical research addressing earnings management? What are the limitations and strengths of current empirical models? |
| reaps pharma llc: Pioneering Portfolio Management David F. Swensen, 2009-01-06 In the years since the now-classic Pioneering Portfolio Management was first published, the global investment landscape has changed dramatically -- but the results of David Swensen's investment strategy for the Yale University endowment have remained as impressive as ever. Year after year, Yale's portfolio has trumped the marketplace by a wide margin, and, with over $20 billion added to the endowment under his twenty-three-year tenure, Swensen has contributed more to Yale's finances than anyone ever has to any university in the country. What may have seemed like one among many success stories in the era before the Internet bubble burst emerges now as a completely unprecedented institutional investment achievement. In this fully revised and updated edition, Swensen, author of the bestselling personal finance guide Unconventional Success, describes the investment process that underpins Yale's endowment. He provides lucid and penetrating insight into the world of institutional funds management, illuminating topics ranging from asset-allocation structures to active fund management. Swensen employs an array of vivid real-world examples, many drawn from his own formidable experience, to address critical concepts such as handling risk, selecting advisors, and weathering market pitfalls. Swensen offers clear and incisive advice, especially when describing a counterintuitive path. Conventional investing too often leads to buying high and selling low. Trust is more important than flash-in-the-pan success. Expertise, fortitude, and the long view produce positive results where gimmicks and trend following do not. The original Pioneering Portfolio Management outlined a commonsense template for structuring a well-diversified equity-oriented portfolio. This new edition provides fund managers and students of the market an up-to-date guide for actively managed investment portfolios. |
| reaps pharma llc: Safe Enough to Soar Frederick A. Miller, Judith Katz, 2018-11-06 Some organizations pay a great deal of attention to ensuring the physical safety of their team members, but do the team members feel safe enough to speak up and raise tough concerns or share bold and still-in-formation ideas? In this book, bestselling authors and inclusion experts Frederick A. Miller and Judith H. Katz introduce the concept of interaction safety and demonstrate how it can help create a work environment of trust, inclusion, and collaboration. Interaction safety encourages reasonable risk-taking and inspires every individual to be brave enough to reach for higher goals and more ambitious possibilities. When interaction safety exists, people know they will not be penalized, ostracized, demoted, made small, discounted, or shunned because of their thoughts, contributions, and conversations. Individuals feel encouraged and empowered and can achieve more together than they would alone. Miller and Katz provide a four-level model for assessing and increasing the interaction safety in organizations, illustrated by short scenarios taken from real-life situations. They offer concrete actions team members, leaders, and organizations can take to build and maintain a productive, collaborative, and innovative environment in which people do their best work individually and collectively. When interaction safety is a way of life, the energy people used to spend walking on eggshells, trying to get their ideas heard, navigating minefields, or avoiding those they distrust can instead be put toward doing their best work and winning bigger for the organization. With a culture of openness and true collaboration, both the organization and individuals can soar! |
| reaps pharma llc: International Human Resource Management Peter Dowling, 2013 |
| reaps pharma llc: The American Opioid Epidemic Michael T. Compton, M.D., M.P.H., Marc W. Manseau, M.D., M.P.H., 2018-12-31 The American Opioid Epidemic: From Patient Care to Public Health provides practicing psychiatrists, trainees, and other mental health professionals with the latest information on opioid addiction, including misuse of heroin and other illicit opioids, the role of prescription analgesic opioids, and recent overdose trends. Although highly effective in relieving acute pain, opioids can cause untold damage to people's lives, health, and social structures. Recognizing the efficacy of these drugs when prescribed appropriately, the editors call not for eliminating access or for incarcerating those who are addicted, but for changing the patterns of prescribing and use. The crisis is analyzed by expert contributors from a wide variety of perspectives, they address issues of epidemiology and toxicology, prevention and harm reduction, and common comorbidities. Stressing that prevention and treatment do work, expert contributors provide down-to-earth, public-health-focused strategies that clinicians and public health workers alike will find indispensable. Moreover, the use of clinical vignettes and key chapter points help ground the reader and highlight the most important concepts. -- Publisher. |
| reaps pharma llc: Free, Fair, and Alive David Bollier, Silke Helfrich, 2019-09-03 Free, Fair, and Alive is a penetrating cultural critique, table-pounding political treatise, and practical playbook for commoning -- free, self-organizing systems ranging from alternative currencies to open-source everything. It presents a bold and compelling alternative to the dead-end, predatory market-state system. |
| reaps pharma llc: Freedom of Expression® Kembrew McLeod, 2005 Publisher Description |
| reaps pharma llc: Digital Advertising Shelly Rodgers, Esther Thorson, 2017-02-17 Digital Advertising offers a detailed and current overview of the field that draws on current research and practice by introducing key concepts, models, theories, evaluation practices, conflicts, and issues. With a balance of theory and practice, this book helps provide the tools to evaluate and understand the effects of digital advertising and promotions campaigns. New to this edition is discussion of big data analysis, privacy issues, and social media, as well as thought pieces by leading industry practitioners. This book is ideal for graduate and upper-level undergraduate students, as well as academics and practitioners. |
| reaps pharma llc: Dreamland (YA edition) Sam Quinones, 2019-07-16 As an adult book, Sam Quinones's Dreamland took the world by storm, winning the NBCC Award for General Nonfiction and hitting at least a dozen Best Book of the Year lists. Now, adapted for the first time for a young adult audience, this compelling reporting explains the roots of the current opiate crisis. In 1929, in the blue-collar city of Portsmouth, Ohio, a company built a swimming pool the size of a football field; named Dreamland, it became the vital center of the community. Now, addiction has devastated Portsmouth, as it has hundreds of small rural towns and suburbs across America. How that happened is the riveting story of Dreamland. Quinones explains how the rise of the prescription drug OxyContin, a miraculous and extremely addictive painkiller pushed by pharmaceutical companies, paralleled the massive influx of black tar heroin--cheap, potent, and originating from one small county on Mexico's west coast, independent of any drug cartel. Introducing a memorable cast of characters--pharmaceutical pioneers, young Mexican entrepreneurs, narcotics investigators, survivors, teens, and parents--Dreamland is a revelatory account of the massive threat facing America and its heartland. |
| reaps pharma llc: Burger King of Florida, Inc. V. Hoots , 1968 |
| reaps pharma llc: Recommendations to the Congress United States. Congress. Pepper Commission, 1990 |
| reaps pharma llc: Recovery in Mental Health Michaela Amering, Margit Schmolke, 2009-06-22 Winner of Medical Journalists’ Association Specialist Readership Award 2010 Recovery is widely endorsed as a guiding principle of mental health policy. Recovery brings new rules for services, e.g. user involvement and person-centred care, as well as new tools for clinical collaborations, e.g. shared decision making and psychiatric advance directives. These developments are complemented by new proposals regarding more ethically consistent anti-discrimination and involuntary treatment legislation, as well as participatory approaches to evidence-based medicine and policy. Recovery is more than a bottom up movement turned into top down mental health policy in English-speaking countries. Recovery integrates concepts that have evolved internationally over a long time. It brings together major stakeholders and different professional groups in mental health, who share the aspiration to overcome current conceptual reductionism and prognostic negativism in psychiatry. Recovery is the consequence of the achievements of the user movement. Most conceptual considerations and decisions have evolved from collaborations between people with and without a lived experience of mental health problems and the psychiatric service system. Many of the most influential publications have been written by users and ex-users of services and work-groups that have brought together individuals with and without personal experiences as psychiatric patients. In a fresh and comprehensive look, this book covers definitions, concepts and developments as well as consequences for scientific and clinical responsibilities. Information on relevant history, state of the art and transformational efforts in mental health care is complemented by exemplary stories of people who created through their lives and work an evidence base and direction for Recovery. This book was originally published in German. The translation has been fully revised, references have been amended to include the English-language literature and new material has been added to reflect recent developments. It features a Foreword by Helen Glover who relates how there is more to recovery than the absence or presence of symptoms and how health care professionals should embrace the growing evidence that people can reclaim their lives and often thrive beyond the experience of a mental illness. Comments on German edition: It is fully packed with useful information for practitioners, is written in jargon free language and has a good reading pace. Theodor Itten, St. Gallen, Switzerland and Hamburg, Germany This book is amazingly positive. It not only talks about hope, it creates hope. Its therapeutic effects reach professional mental health workers, service users, and carers alike. Fleet-footed and easily understandable, at times it reads like a suspense novel. Andreas Knuf, pro mente sana, Switzerland 'This is the future of psychiatry' cheered a usually service-oriented manager after reading the book. We might not live to see it.' Ilse Eichenbrenner, Soziale Psychiatrie, Germany |
| reaps pharma llc: Drug Dealer, MD Anna Lembke, 2016-11-15 The disturbing connection between well-meaning physicians and the prescription drug epidemic. Three out of four people addicted to heroin probably started on a prescription opioid, according to the director of the Centers for Disease Control and Prevention. In the United States alone, 16,000 people die each year as a result of prescription opioid overdose. But perhaps the most frightening aspect of the prescription drug epidemic is that it’s built on well-meaning doctors treating patients with real problems. In Drug Dealer, MD, Dr. Anna Lembke uncovers the unseen forces driving opioid addiction nationwide. Combining case studies from her own practice with vital statistics drawn from public policy, cultural anthropology, and neuroscience, she explores the complex relationship between doctors and patients, the science of addiction, and the barriers to successfully addressing drug dependence and addiction. Even when addiction is recognized by doctors and their patients, she argues, many doctors don’t know how to treat it, connections to treatment are lacking, and insurance companies won’t pay for rehab. Full of extensive interviews—with health care providers, pharmacists, social workers, hospital administrators, insurance company executives, journalists, economists, advocates, and patients and their families—Drug Dealer, MD, is for anyone whose life has been touched in some way by addiction to prescription drugs. Dr. Lembke gives voice to the millions of Americans struggling with prescription drugs while singling out the real culprits behind the rise in opioid addiction: cultural narratives that promote pills as quick fixes, pharmaceutical corporations in cahoots with organized medicine, and a new medical bureaucracy focused on the bottom line that favors pills, procedures, and patient satisfaction over wellness. Dr. Lembke concludes that the prescription drug epidemic is a symptom of a faltering health care system, the solution for which lies in rethinking how health care is delivered. |
| reaps pharma llc: Understanding the Entrepreneurial Mind Alan L. Carsrud, Malin Brännback, 2009-07-30 Interest in the functioning of the human mind can certainly be traced to Plato and Aristotle who often dealt with issues of perceptions and motivations. While the Greeks may have contemplated the human condition, the modern study of the human mind can be traced back to Sigmund Freud (1900) and the psychoanalytic movement. He began the exploration of both conscious and unconscious factors that propelled humans to engage in a variety of behaviors. While Freud’s focus may have been on repressed sexuality our focus in this volume lies elsewhere. We are concerned herein with the expression of the cognitions, motivations, passions, intentions, perceptions, and emotions associated with entrepreneurial behaviors. We are attempting in this volume to expand on the work of why entrepreneurs think d- ferently from other people (Baron, 1998, 2004). During the decade of the 1990s the eld of entrepreneurship research seemingly abandoned the study of the entrepreneur. This was the result of earlier research not being able to demonstrate some unique entrepreneurial personality, trait, or char- teristic (Brockhaus and Horwitz, 1986). It was both a naïve and simplistic search for the “holy grail” of what made entrepreneurs the way they are. However, many of the researchers in this volume have never gave up the belief that a better und- standing of the mind of the entrepreneur would give us a better understanding of the processes that lead to the creation of new ventures. |
| reaps pharma llc: Sterile Product Facility Design and Project Management Jeffrey N. Odum, 2004-03-29 Knowing how to deal with the regulatory issues, understanding the impacts of cleanliness, and recognizing the affect that poor facility layout will have on GMP spaces are only some of the issues an experienced Project Manager must focus on. Completely revised and updated, Sterile Product Facility Design and Project Management, Second Edition provid |
| reaps pharma llc: Pathology Practical Book Harsh Mohan, 2012-11-30 This new edition has been fully revised to help pathology trainees acquire practical knowledge in diagnostic pathology. Divided into eight sections and consisting of 61 exercises, this useful guide discusses techniques and general pathology, and then offers exercises for each discipline within pathology – systemic pathology, cytopathology, haematology, clinical pathology and autopsy. The third edition offers updated images and new exercises for topics of current clinical significance including immunohistopathology, surgical pathology, types of blood samples, anticoagulants and blood collection. Supported by key points, nearly 600 line drawings, specimen photographs and photomicrographs, this practical manual also includes a CD reviewing specimens. Key points Fully revised, new edition offering trainees practical knowledge in diagnostic pathology Consists of 61 exercises covering key disciplines within pathology Includes updated images and new exercises for topics of current clinical significance Includes key points, nearly 600 line drawings, specimen photographs and photomicrographs, and a CD reviewing specimens Previous edition published in 2007 |
| reaps pharma llc: Pain Killer Barry Meier, 2018-05-29 A Pulitzer Prize–winning New York Times reporter exposes the roots of the opioid epidemic at the hands of Purdue Pharma and Raymond and Mortimer Sackler in Pain Killer, a “timely, compelling, important” (The Seattle Times) story of corporate greed and government negligence. “Groundbreaking . . . Pain Killer is the shocking account of the origins of today’s opioid epidemic, the creators of this plague, and the way to help stop it.”—Sam Quinones, author of Dreamland: The True Tale of America’s Opiate Epidemic Between 1999 and 2017, an estimated 250,000 Americans died from overdoses involving prescription painkillers, a plague ignited by Purdue Pharma’s aggressive marketing of OxyContin. Families, working class and wealthy, have been torn apart, businesses destroyed, and public officials pushed to the brink. Meanwhile, the drugmaker’s owners, Raymond and Mortimer Sackler, whose names adorn museums worldwide, made enormous fortunes from the commercial success of OxyContin. In Pain Killer, Barry Meier tells the story of how Purdue turned OxyContin into a billion-dollar blockbuster. Powerful narcotic painkillers, or opioids, were once used as drugs of last resort for pain sufferers. But Purdue launched an unprecedented marketing campaign claiming that the drug’s long-acting formulation made it safer to use than traditional painkillers for many types of pain. That illusion was quickly shattered as drug abusers learned that crushing an Oxy could release its narcotic payload all at once. Even in its prescribed form, Oxy proved fiercely addictive. As OxyContin’s use and abuse grew, Purdue concealed what it knew from regulators, doctors, and patients. Here are the people who profited from the crisis and those who paid the price, those who plotted in boardrooms and those who tried to sound alarm bells. A country doctor in rural Virginia, Art Van Zee, took on Purdue and warned officials about OxyContin abuse. An ebullient high school cheerleader, Lindsey Myers, was reduced to stealing from her parents to feed her escalating Oxy habit. A hard-charging DEA official, Laura Nagel, tried to hold Purdue executives to account. In this updated edition of Pain Killer, Barry Meier breaks new ground in his decades-long investigation into the opioid epidemic. He takes readers inside Purdue to show how long the company withheld information about the abuse of OxyContin and gives a shocking account of the Justice Department’s failure to alter the trajectory of the opioid epidemic and protect thousands of lives. Equal parts crime thriller, medical detective story, and business exposé, Pain Killer is a hard-hitting look at how a supposed wonder drug became the gateway drug to a national tragedy. |
| reaps pharma llc: India and the Challenge of Statelessness Sitharamam Kakarala, Deepika Srivastava, Maanvi Tiku, 2014 |
| reaps pharma llc: Pirate Nation Darren Todd, 2011 'Pirate Nation' is the remarkable story of modern-day digital piracy, and how it affects business, society, creativity and culture, now and in the future. It traces the origins, methods and motivations of modern-day digital pirates, focusing not just on copyright law or file sharing music, but also game, movie, literary and software piracy. |
| reaps pharma llc: Pharmacology and Pharmacotherapeutics, 26e Satoskar, 2020 |
| reaps pharma llc: Strategic Marketing David W. Cravens, Nigel Piercy, 2006 Strategic Marketing 8/e by Cravens and Piercy is a text and casebook that discusses the concepts and processes for gaining the competitive advantage in the marketplace. The authors examine many components of a market-driven strategy, including technology, customer service, customer relationships, pricing, and the global economy. The text provides a strategic perspective andextends beyond the traditional focus on managing the marketing mix. The cases demonstrate how real companies build and implement effective strategies. Author David Cravens is well known in the marketing discipline and was the recipient of the Academy of Marketing Sciencećs Outstanding Marketing Educator Award. Co-author Nigel Piercy, has a particular research interest in market-led strategic change and sales management, for which he has attracted academic and practitioner acclaim in the UK and USA. |
| reaps pharma llc: F&S Index United States Annual , 1999 |
| reaps pharma llc: Strategy, 2008-2009 Dave Ketchen, Alan Eisner, 2008-02-19 Overview: Strategy 08/09 is concisely written to cover the core strategy concepts within strategic management and to do so in a rigorous yet engaging way. This text builds on both real-life examples and academic research and provides appropriate cases chosen specifically for the textbook. Designed by faculty at a focus group, this text will published in 2-color format on an annual basis to ensure that company examples are current and relevant to students and instructors. |
| reaps pharma llc: Intellectual Property Law Parameswaran Narayanan, 2001 |
| reaps pharma llc: The Complete Illustrated Holistic Herbal David Hoffmann, 2003 |
| reaps pharma llc: The Economics of Managerial Decisions Roger D. Blair, Mark Rush, 2020 |
| reaps pharma llc: F&S Index International Annual , 1999 |
About Us - REAPS Nutrition
REAPS established a US subsidiary (REAPS PHARMA LLC), with three automated production lines in the US factory. REAPS has invested in a South Korean factory, becoming a …
About REAPS - reapsgj.com
The US branch (REAPS PHARMA LLC) was established, and the US plant was put into production with three automatic production lines. REAPS invested in the South Korean factory, …
关于REAPS_瑞普斯 - reapsgj.com
成立美国分公司（reaps pharma llc），美国工厂投入生产，具备三条自动生产线。 REAPS入股韩国工厂，成为美卡熊中国区品牌战略运营指定集团，进军口溶膜剂型领域独创口溶膜剂型营养 …
Reaps Pharma, LLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Reaps Pharma, LLC of Chino, CA. Get the latest business insights from Dun & Bradstreet.
Reaps Pharma LLC | BBB Business Profile - Better Business Bureau
BBB Accredited since 5/16/2025. Diet Products in Chino, CA. See BBB rating, reviews, complaints, get a quote and more.
Reaps Pharma LLC · 1312 17th Street Suite 890, Denver, CO 80202
REAPS PHARMA LLC (Entity #20231737762) is a DLLC in Denver, Colorado registered with the Colorado Department of State (CDOS). The entity was formed on July 18, 2023 in the …
Reaps Pharma, LLC - Company Profile - Corporation Wiki
Aug 9, 2019 · View company leaders and background information for Reaps Pharma, LLC. Search our database of over 100 million company and executive profiles.
Online Exhibition - ciie.org
Reaps Pharmaceutical Co. , Ltd. was founded in 2019, headquartered in Chino, California, USA, the main business is the import of dietary supplements OEM services and brand operations …
REAPS PHARMA LLC - Colorado Company
Jul 18, 2023 · REAPS PHARMA LLC (ID number: 20231737762) was incorporated on 07/18/2023 in Colorado. Their business is recorded as DLLC. The Company's current operating status is …
REAPS PHARMA, LLC in Chino, CA | Company Info & Reviews
Mar 5, 2025 · REAPS PHARMA, LLC is a California Limited-Liability Company - Ca filed on August 9, 2019. The company's filing status is listed as Active and its File Number is …
About Us - REAPS Nutrition
REAPS established a US subsidiary (REAPS PHARMA LLC), with three automated production lines in the US factory. REAPS has invested in a South Korean factory, becoming a …
About REAPS - reapsgj.com
The US branch (REAPS PHARMA LLC) was established, and the US plant was put into production with three automatic production lines. REAPS invested in the South Korean factory, …
关于REAPS_瑞普斯 - reapsgj.com
成立美国分公司（reaps pharma llc），美国工厂投入生产，具备三条自动生产线。 REAPS入股韩国工厂，成为美卡熊中国区品牌战略运营指定集团，进军口溶膜剂型领域独创口溶膜剂型营养 …
Reaps Pharma, LLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Reaps Pharma, LLC of Chino, CA. Get the latest business insights from Dun & Bradstreet.
Reaps Pharma LLC | BBB Business Profile - Better Business Bureau
BBB Accredited since 5/16/2025. Diet Products in Chino, CA. See BBB rating, reviews, complaints, get a quote and more.
Reaps Pharma LLC · 1312 17th Street Suite 890, Denver, CO 80202
REAPS PHARMA LLC (Entity #20231737762) is a DLLC in Denver, Colorado registered with the Colorado Department of State (CDOS). The entity was formed on July 18, 2023 in the …
Reaps Pharma, LLC - Company Profile - Corporation Wiki
Aug 9, 2019 · View company leaders and background information for Reaps Pharma, LLC. Search our database of over 100 million company and executive profiles.
Online Exhibition - ciie.org
Reaps Pharmaceutical Co. , Ltd. was founded in 2019, headquartered in Chino, California, USA, the main business is the import of dietary supplements OEM services and brand operations …
REAPS PHARMA LLC - Colorado Company
Jul 18, 2023 · REAPS PHARMA LLC (ID number: 20231737762) was incorporated on 07/18/2023 in Colorado. Their business is recorded as DLLC. The Company's current operating status is …
REAPS PHARMA, LLC in Chino, CA | Company Info & Reviews
Mar 5, 2025 · REAPS PHARMA, LLC is a California Limited-Liability Company - Ca filed on August 9, 2019. The company's filing status is listed as Active and its File Number is …
